The addition of an RNA vaccine containing mRNAs encoding CLDN6 (CARVac), when combined with human CLDN6 CAR-Ts, significantly enhanced CAR-T expansion, memory formation and efficacy compared to the delivery of CLDN6 CAR-Ts alone across multiple tumor models, including syngeneic gastric and lung models as well as a xenograft ovarian cancer model (100). Here, CLDN6 is linked to ovarian cancer.